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Summary Western blotting analysis of the p21 ras oncoprotein was performed in seven normal laryngeal
mucosa specimens and 43 primary laryngeal cancers. Varying p21 levels, expressed as optical density (OD),
were found in normal mucosa (median 1.94 OD, range 0.90-2.17 OD) and in primary laryngeal tumours
(median 1.74 OD, range 0.30-6.37 OD). When p21 expression in laryngeal cancer was compared with the
normal counterpart, higher levels were found in neoplastic than in normal laryngeal tissue (median 2.54 OD,
range 1.76-6.37 OD, vs median 1.94 OD, range 0.90-2.17 OD) (P = 0.023). Immunohistochemical analysis
demonstrated that most of the tumour cells (more than 70%) were immunostained while the stromal
component was unreactive. No correlation between p21 expression and tumour location, stage and histo-
pathological grade was observed. The correlation between ras p21 protein expression and epidermal growth
factor receptor (EGFR) levels was also investigated. EGFR-positive cases did not show any difference in p21
expression with respect to EGFR-negative cases (median 1.52 OD, range 0.30-6.37 OD, vs median 1.84 OD,
range 0.93-3.71 OD). Our findings suggest that overexpression of p21 protein is associated with a malignant
phenotype in laryngeal cancer. Further studies should be undertaken to evaluate whether the assessment of
p21 protein expression may have clinical significance in laryngeal cancer.
Laryngeal cancer constitutes up to 2% of all cancers, and
90-95% are squamous cell carcinomas (Powell et al., 1983).
The aetiology of laryngeal cancer has yet to be clarified,
although it seems to be closely related to alcohol and tobacco
abuse. Only now are the molecular changes associated with
laryngeal cancer being elucidated.
Several transforming cellular oncogenes have been isolated
from a variety of human tumours, and their characterisation
has significantly contributed to an understanding of cancer at
the molecular level. In particular, attention has been focused
on the ras gene family, which consists of three functional
genes encoding a 21 kDa protein located on the inner surface
of the plasma membrane and characterised by a guanosine
S'-triphosphatase activity (Barbacid, 1987).
The normal function of p21 has been partially clarified in
yeast Saccharomyces cerevisiae (Hughes et al., 1990) but is
still unknown in mammals; however, because of some struc-
tural similarity to the so-called G-proteins acting as 'signal
transducers' (Gilman, 1984), it has been suggested that the
p21 protein may be involved in the transduction of extracel-
lular signals controlling cell growth.
The finding that epidermal growth factor (EGF), a peptide
acting through a specific plasma membrane receptor (EGFR)
(Carpenter, 1987), increases the level of the active p21-GTP
complex in ras oncogene-transformed cells suggests that the
biological effects induced by EGF, like those induced by
platelet-derived growth factor, may be associated with p21
oncoprotein activation (Satoh et al., 1990).
Previous studies have reported enhanced p21 expression in
human bladder (Viola et al., 1985), lung (Kurzrock et al.,
1986), breast (Walker et al., 1988), ovarian (Rodenburg et
al., 1988; Scambia et al., 1993a), endometrial (Long et al.,
1988; Scambia et al., 1993b) and squamous cell cancers
(Tanaka et al., 1986; Satoh et al., 1992). Moreover, activa-
tion of the ras oncogene by mutation at amino acid position
12, 13 or 61, or amplification of the gene product, has been
demonstrated in different tumour types (Spandidos, 1987;
Smit et al., 1988; vant' Veer et al., 1988; Volgelstein et al.,
1988; Boltz et al., 1989). At present very few data are
available on ras p21 expression in laryngeal cancer.
Previous studies analysing the alterations of ras at the gene
level did not demonstrate amplification or rearrangement,
while mRNA overexpression was observed in 22% of cases
(Sheng et al., 1990). The aim of the study was to assess the
expression of the p21 oncoprotein in normal and malignant
laryngeal tissues by using the Western blotting technique.
The correlation between p21 levels and histopathological
parameters and the distribution of p21 levels according to
EGFR status were also analysed.
Materials and methods
Tissue samples
The study included seven normal mucosa specimens and 43
primary human laryngeal tumours.
Thirty-nine of the tumour patients were males and four
were females. Patients were aged between 34 and 80 years
(median age 61 years). All tumours were histologically
squamoepidermoid carcinomas. Tumour site was classified as
glottic or supraglottic and was defined as transglottic when
the extension of disease did not permit identification of the
origin of the tumour. Tumours were staged according to
TNM classification (American Joint Committee on Cancer,
1993) and histologically graded as well- (GI), moderately
(G2) and poorly (G3) differentiated tumours.
Twenty-three patients underwent radical laryngectomy,
while 20 had conservative surgery (16 supraglottic laryngec-
tomies, two cordectomies, two hemilaryngectomies). Fifteen
patients in whom there was lymph node involvement under-
went therapeutic neck dissection.
The characteristics of the tumour patients are summarised
in Table I.
Expression of the p21 protein was also analysed in seven
normal laryngeal mucosa specimens obtained from the same
tumour patients in a corresponding non-tumour area of the
larynx. At the time of surgery a representative specimen of
normal tissue was set aside for histopathological examina-
tion. The specimens were frozen immediately in liquid nitro-
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Table I Patient characteristics
No. of patients (%)
Total 43
Sex
Male 39 (91)
Female 4 ( 9)
Age (years)
<60 18 (42)
>60 25 (58)
Tumour location
Supraglottic 19 (44)
Glottic 11 (26)
Transglottic 13 (30)
Stagea
I 11 (26)
II 12 (28)
III 14 (32)
IV 6 (14)
Lymph node involvement
No 28 (65)
Yes 15 (35)
Histopathological gradeb
G1 3(7) G2 28 (65)
G3 12 (28)
Type of surgery
Conservative 20 (46)
Radical 23 (54)
aStage I =TI, NO, MO; II= T2, NO, MO; III= TI, 2, 3, NO, MO;
IV=T4, NO 1, MO, or any T, N2, 3, MO, or any T, any N, MI
(American Joint Committee on Cancer, 1993). bGI, G2, G3 = well-,
moderately, and poorly differentiated tumours respectively.
gen after surgical removal and stored at - 80°C until pro-
cessed.
Chemicals and reagents
Acrylamide, N,N-methylene-bis-acrylamide, sodium dodecyl
sulphate, N,N,N-tetramethylethylenediamine, low molecular
weight marker proteins and nitrocellulose membrane were
purchased from Bio-Rad (Richmond, CA, USA). Aprotinin
was from Boehringer Mannheim (Germany). Rabbit anti-rat
immunoglobulin G was obtained from Dako Immunoglo-
bulins (Copenhagen), and '25I-labelled protein A
(30 yCipg-') was from Amersham (Arlington Heights, IL,
USA). MAb Y13-259, a rat-derived monoclonal antibody
that immunoprecipitates both the point-mutated and normal
products of the ras gene family (Ha-N-Ki), was purchased
from Oncogene Science (New York, NY, USA).
Preparation ofthe tissue lysates
Frozen tissues were pulverised and homogenised with five
volumes of ice-cold buffer consisting of 0.1 M sodium
chloride, 5 nM magnesium chloride, 1% Nonidet P-40, 0.5%
sodium deoxycholate, 2 units of kallikrein inhibitor per ml of
(bovine) aprotinin and 20 nM Tris-HCl, pH 7.4. The
homogenate was centrifuged at 750g for 20 min at 4°C and
the resulting supernatants were frozen at - 80°C until assay.
The determination of the protein concentration of lysates
was performed according to the method of Bradford (1976).
Detection and estimation ofthe p21 protein
The Western blotting technique was used for p21 protein
determination (De Bortoli et al., 1985). After 3 min boiling,
lysate proteins were separated by 12% sodium dodecyl sul-
phate (SDS) polyacrylamide gel electrophoresis. The gels
were transblotted to nitrocellulose filters in Tris-glycine
buffer (25 mM Tris, 192 mM glycine, 20% methanol, pH 7.4)
for 5 h at 60 V. Nitrocellulose sheets were washed and unoc-
cupied binding sites were saturated with 3% bovine serum
albumin in NTE-NP40 (50 mM Tris-HCl pH 7.5, 2 mM
EDTA, 150 mM sodium chloride, 0.1% Nonidet P-40) for 3 h
at 37°C. Then the filters were sequentially incubated with
buffer containing Y13-259 rat monoclonal antibody (Furth et
al., 1982) (diluted 1:300) directed against Ha-MUSV-encoded
p21 for 4 h at 4°C, and with rabbit anti-rat IgG (diluted
1:500) and 5 x 10E5 c.p.m. ml-' '25I-labelled protein A for
1 h at 4°C. Filters were air dried and exposed to Kodak
XAR films for 48 h at - 80°C. Comparison of the resulting
autoradiographs with others in which normal rat serum was
substituted for p21 monoclonal antibody permitted the
identification of the p21 band. Computer-assisted image
analysis of autoradiographs was performed in order to quan-
tify the intensity of the bands. In order to standardise the
analysis, a constant amount (100 ftg) of protein of every
sample was loaded on SDS gels. In addition a control p21
derived from NRK (normal rat kidney) cells transformed by
Harvey murine sarcoma virus was used in all experiments.
In order to better ensure that the p21 kDa band we
detected was the ras p21 oncoprotein, an experiment was
carried out (Figure 1) in which normal rat serum was used
instead of specific anti-p21 Y13-259 MAb. The band of
21 kDa was absent when normal rat serum was utilised.
Optical densitometric values of the band intensities (the
integral of the absorbance) (OD) were used for statistical
analysis. Western blotting analysis was performed in different
specimens of the same tumour sample revealing an intra-
tumour homogeneity of p21 expression (coefficient of varia-
tion 14%). Intra-sample variation of OD readings ranged
from 2 to 3.8%. The cut-off utilised to define p21 status was
2.00 OD, corresponding to the median value of p21 in
laryngeal carcinomas.
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Figure 1 Western blotting analysis of p21 oncoprotein in the
same six patients with primary laryngeal cancer incubated with
specific anti-p21 Y13-259 MAb a, or with normal rat serum b.
Lane S: molecular weight standards.
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Figure 2 Western blotting analysis ofp21 oncoprotein in normal
laryngeal mucosa specimens (lanes 1-3) and neoplastic laryngeal
tumours (lanes 4-13). Lane S: molecular weight standards.p21 ONCOPROTEIN EXPRESSION IN PRIMARY LARYNGEAL CANCER 997
EGFR measurement
a An aliquot of the pulverised tissues was homogenised in
99. ice-cold buffer consisting of 25 mM Tris, 1.5 mM sodium
oxide, 10 mM monothioglycerol and 20% glycerol
(TENMG). Cytosol and membrane fractions were prepared
K as previously described (Battaglia et al., 1988). The crude
homogenate was centrifuged at 7,000g for 20min at 0°C.
The supernatants were then centrifuged at 105,000 g for
75 min at 0°C.
The membrane pellet was resuspended in 25 mM Tris,
1.5 mM EDTA, 5mM sodium azide (NaN3), 20% glycerol
and 10 mM magnesium chloride (TENG + magnesium
chloride). Aliquots of the suspension (100 il containing
300-500 jig ofprotein) were incubated with [1251I]EGF (NEN
Dupont De Nemours) (specific activity 780,000 Ci mmol '
(3.2 nM) in the presence or absence of unlabelled EGF (Boeh-
ringer Mannheim, Germany) (1 iLM) for 16 h at room tempera-
ture in a final volume of 400 l1. Binding was stopped by
addition of 3 ml of 25 mM Tris, 20% glycerol, 5 mM and
0.1% bovine serum albumin. Pellets were obtained by centri-
fugation at 2,000 g for 20 min at 0°C and counted in a
gamma-counter for 1 min. Results were expressed as femto-
moles per mg of membrane protein (fmol mg-' protein).
EGFR status was defined using a cut-off of 8.00 fmol mg-' ....i.. protein, corresponding to the median EGFR levels of
b laryngeal carcinomas (data not shown).
Immunohistochemical staining
Immunohistochemical analysis of the p21 protein was per-
formed by the avidin-biotin-peroxidase complex (ABC)
method (Vector Laboratories, Burlingame, CA, USA) with
the Y13-259 anti-human p21 rat monoclonal antibody
(MAb) (Oncogene Science). For this purpose a representative
sample of each tumour was fixed according to routine
laboratory procedures in 10% buffered formalin (pH 7.4) and
embedded in paraffin wax. Five micron sections were
dewaxed, rehydrated, washed in phosphate-buffered saline
(PBS) solution and then incubated for 5 min in 3% (w/v)
hydrogen peroxide solution at room temperature to block
any endogenous peroxidase. All sections were washed again
in PBS solution and incubated with normal serum as the
blocking reagent to minimise non-specific binding. A 1:100
dilution of the monoclonal antibody specific for p21 was
applied to the specimen. Normal rat IgG (Sigma, St Louis,
MO, USA) was used (1:100 in PBS) as a negative control.
The sections were subsequently incubated with the
biotinylated horse anti-rat IgG (1:200 in PBS), and with the
ABC reagent for 30min at room temperature. Finally, the
C sections were washed in PBS, stained by incubation with
0.5 mg ml' 3-3'-diaminobenzidine (Sigma) in 0.01% hyd-
rogen peroxide for 5 min, and counterstained with haematox-
ylin.
Statistical analysis
Student's t-test was used to analyse the distribution of p21
oncoprotein in normal and neoplastic laryngeal tissues. Since
p21 levels are not normally distributed, the Mann-Whitney
rank-sum non-parametric test was used to analyse p21 ex-
pression according to the histopathological parameters of the
cancer patients and EGFR expression.
Figure 3 A representative example of immunohistochemical
analysis ofp21 ras in primary laryngeal cancer. a, Control section
with normal rat IgG as primary antibody. b, Section incubated
with specific Y13-259 anti-ras monoclonal antibody. Most of the
tumour cells (more than 70%) show immunoreaction. c,
Magnified sections of primary laryngeal cancer. p21-specific
immunostaining is diffusely located in the cytoplasm of tumour
cells.998 G. SCAMBIA et al.
Results
Figure 2 shows a representative example of Western blotting
analysis of the p21 oncoprotein in normal and neoplastic
largyngeal tissues. We found that both normal and neoplastic
tissues contained detectable amounts of p21.
In Figure 3 the p21 immunohistochemical staining of
primary laryngeal cancer is shown. The immunoreaction of
p21 was heterogeneous. However, most of the cancer cells
(more than 70%) were p21 positive, while the stromal com-
ponent was unreactive. The specific p21 staining is seen as
diffusely located in the cytoplasm of the tumour cells.
The densitometric evaluation of p21 levels in normal and
neoplastic laryngeal tissues is shown in Figure 4. Scattered
p21 OD values were found in normal mucosa (median 1.94
OD, range 0.90-2.17 OD) and in primary laryngeal tumours
(median 1.74 OD, range 0.30-6.37 OD). When p21 expres-
sion in laryngeal cancer was compared with the normal
counterpart, higher levels were found in neoplastic than in
normal laryngeal tissue (median 2.54 OD, range 1.76-6.37
OD vs median 1.94 OD, range 0.90-2.17 OD) (P = 0.023).
In Table II the distribution of densitometric p21 values
according to histopathological characteristics in 43 primary
laryngeal tumours is shown. No correlation between p21
expression and tumour location, stage of disease or his-
topathological grade was observed.
No correlation was found between EGFR levels and p21
densitometric band intensities (data not shown). Moreover
we investigated the distribution of p21 OD values according
to EGFR status, which was defined using a cut-off of
8.00 fmol mg-' protein. This value corresponds to the
median value of EGFR levels in our tumour series and was
previously demonstrated (Maurizi et al., 1992) to be the best
discriminating value.
EGFR-positive cases do not show any significant difference
in p21 OD with respect to EGFR-negative cases (median
1.52 OD, range 0.30-6.37 OD vs median 1.84, range
0.93-3.71 OD) (Table III).
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Figure 4 Distribution of p21 densitometric band intensities (exp-
ressed as optical density) in normal and neoplastic laryngeal
tissues. Lines refer to the samples of normal mucosa and primary
tumour derived from the same patient.
Table II Distribution of densitometric p21 band intensities
according to histopathological and clinical characteristics of 43
primary laryngeal carcinomas
No. of Median Range
patients value (OD) (OD)
Tumour location
Supraglottic 19 1.78 0.30-6.37
Glottic 11 1.26 0.40-3.71
Transglottic 13 2.11 1.03-5.47
Stage
I 11 1.80 0.83-6.37
II 12 1.48 0.80-2.90
III 14 1.97 0.30-5.47
IV 6 2.40 1.26-4.95
Lymph node involvement
No 28 1.55 0.83-5.47
Yes 15 1.99 0.30-6.37
Histopathological grade
GI 3 1.50 1.25- 1.76
G2 28 1.84 0-83 -5.47
G3 12 1.55 0.30-6.37
Table III Correlation of p21 oncoprotein expression with EGFR
status in 43 primary laryngeal tumours
p21 expression
No. of (OD)
patients (%) Median Range P-value
EGFR a 22 (51) 1.84 0.93-3.71
EGFR+ 21 (49) 1.52 0.30-6.37 n.s.
a8.00 fmolmg-' protein was used as an arbitrary cut-off to define
EGFR status.
Discussion
To our knowledge, this is the first study using the Western
blotting technique to analyse p21 protein expression in nor-
mal laryngeal tissues and laryngeal tumours.
Varying levels of the p21 protein were observed in normal
laryngeal specimens, as reported in other normal tissues
(Walker et al., 1988; Scambia et al., 1993a,b), suggesting that
p21 may be involved in normal cell functions and
metabolism. We found that p21 levels were higher in neoplas-
tic than in normal tissues when samples from the same
patients were compared, thus confirming previous observa-
tions reported in breast (Spandidos et al., 1984), colon (Gal-
lick et al., 1985), ovarian (Scambia et al., 1993a) and
endometrial (Scambia et al., 1993b) tissues. These findings
suggest that p21 overexpression may be associated with a
malignant phenotype.
As far as laryngeal cancer is concerned, the presence of a
wide range of p21 levels supports the hypothesis that overex-
pression of the p21 protein may play a role in the biology of
laryngeal cancer cells, thus characterising more aggressive
tumours. ras gene amplification has not been reported until
now in laryngeal cancer (Merritt et al., 1990; Sheng et al.,
1990). Therefore it is conceivable that transcriptional or post-
transcriptional mechanisms are involved in p21 ras overexp-
ression in laryngeal tumour cells. The MAb used in our study
recognises both the abnormal and normal products of the
three ras genes. The percentage of ras gene mutations has
been reported to range from 4 to 14% in head and neck
carcinomas (Sheng et al., 1990; Anderson et al., 1992; Irish,
1992), whereas there is no evidence of ras gene mutation in
laryngeal tumours (Anderson et al., 1992). It is conceivable
that the role of altered p21 protein in laryngeal cancer is
irrelevant and that the overexpression of each of the p21
gene products is responsible for ras-induced transformation.
Despite the evidence that the p21 oncoprotein may be
involved in mediating EGF mitogenic signals (Kamata &
Feramisco, 1984), ras p21 expression was not related to
EGFR levels as previously reported in gynaecological
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tumours (Scambia et al., 1993a,b). It could be suggested that
the EGF/EGFR system does not interact with ras or that the
two systems are differentially regulated in laryngeal tumours.
The prognostic characterization of laryngeal cancer is still
inadequate, and attempts should be made to identify new
factors which could give further insight into tumour cell
biology and the clinical evolution of this neoplasia.
It has been reported that p21 overexpression is associated
with tumour progression and poor prognosis in breast cancer
(Clair et al., 1987). Moreover, our data indicate that p21
overexpression may have a negative prognostic value in
ovarian cancer (Scambia et al., 1993a).
Since the number of cases examined by us does not allow
the evaluation of the possible role of p21 expression in the
prognostic characterisation of laryngeal cancer patients, pro-
spective studies are now in progress in our institute.
This study was supported by the special CNR project ACRO.G.F. is
the recipient of a fellowship from the Italian Association for Cancer
Research (AIRC).
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